印度曾暴露于贝达喹啉的结核病患者中贝达喹啉耐药与治疗结局:多中心回顾性队列研究
该多中心回顾性队列研究纳入2020年12月至2022年12月印度两家中心117例曾暴露于贝达喹啉(BDQ)的结核病患者,42例(36%)检出BDQ耐药株。102例启动治疗,BDQ耐药患者不良结局风险显著高于敏感患者(RR 2.1,95%CI 1.1-2.8,P<.001),耐药者中87%(33/38)出现不良结局。作者建议实施BDQ药敏试验、开发可负担的快速耐药检测并加强新药研发。
要点
- 117例BDQ暴露患者中42例(36%)检出BDQ耐药株。
- BDQ耐药患者不良结局风险为敏感患者的2.1倍(RR 2.1,95%CI 1.1-2.8,P<.001)。
- BDQ耐药者中87%(33/38)不良结局:40%死亡、40%治疗失败、8%失访。
核心结论
- 曾接受治疗的患者中BDQ耐药率令人担忧,并导致治疗结局不佳。
- 作者建议实施BDQ药敏试验、开发可负担且准确的BDQ耐药快速检测,并加强新型结核药物的研发。
研究设计与样本
- 多中心回顾性队列研究,纳入印度德里国家结核与呼吸疾病研究所和孟买无国界医生诊所2020年12月至2022年12月117例曾暴露于BDQ的结核病患者。
- 对所有BDQ暴露患者进行BDQ表型药敏试验,治疗方案根据暴露史、合并症、药物相互作用、既往药物不良反应及药敏结果个体化制定。
主要发现
- 117例BDQ暴露患者中42例(36%)为BDQ耐药株。
- 中位年龄24岁(IQR 22-32),女性63例(54%),94%为肺结核。
- BDQ耐药患者年龄更大(中位年龄27岁 vs 23岁,P=.04),更易有肺空洞(RR 1.8,95%CI 1.1-3.1,P=.02),且更易对氯法齐明耐药(RR 2.3,95%CI 1.5-3.6,P=.001)。
- 共102例患者启动治疗,BDQ耐药患者较BDQ敏感患者不良结局风险更高(RR 2.1,95%CI 1.5-2.8,P<.001)。
- BDQ耐药患者中87%(33/38)出现不良治疗结局:15例(40%)死亡,15例(40%)治疗失败,3例(8%)失访。
关键数值与推荐
- BDQ耐药定义为BDQ表型药敏试验检出耐药株。
- 不良结局包括死亡、治疗失败和失访。
临床怎么用
- 作者建议实施BDQ药敏试验以预防治疗失败。
- 作者建议开发可负担且准确的BDQ耐药快速检测。
- 作者建议加强新型结核药物的研发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. The emergence of resistance to BDQ, a key drug in treating MDR-TB, poses significant threats to TB treatment effectiveness. METHODS: The National Institute of Tuberculosis and Respiratory Diseases in Delhi and the Médecins Sans Frontières clinic in Mumbai provide BDQ, delamanid, and carbapenem-based regimens for patients with suspected or confirmed treatment failure. BDQ phenotypic drug-susceptibility testing (DST) was performed for all BDQ-exposed patients. Treatment regimens were individualized based on exposure history, comorbidities, drug interactions, prior adverse drug reactions, and DST results. RESULTS: Of 117 BDQ-exposed patients from December 2020-December 2022, 42 (36%) exhibited a BDQ-resistant strain. Median (IQR) age was 24 (22-32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with a BDQ-resistant strain were older (median age: 27 vs 23 years; P = .04), more likely to have lung cavities (risk ratio [RR]: 1.8; 95%-CI: 1.1-3.1; P = .02), and be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5-3.6; P = .001). Overall, 102 patients initiated treatment. Patients with BDQ-resistance had higher risk of unfavorable outcomes compared with BDQ-susceptible patients (RR:2.1; 95%-CI: 1.5-2.8; P < .001). Overall, 87% (33/38) of patients with BDQ-resistance experienced unfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%) were lost-to-follow-up. CONCLUSIONS: The study highlights a concerning rate of BDQ-resistance among previously treated patients, resulting in poor treatment outcomes. To prevent treatment failure, we recommend implementing BDQ-DST, developing affordable and accurate rapid tests for BDQ-resistance, and intensifying research and development efforts for newer TB drugs.
引用
- Singla R, Khan S, Silsarma A, et al. Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study. Clin Infect Dis. 2025. PMID: 40079698. doi:10.1093/cid/ciaf068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。